Tag: bioMérieux
bioMérieux: Invest Securities reiterates its opinion – 03/15/2024 at 4:50 p.m.
Member Login Customer Login (CercleFinance.com) – While lowering its price target from 127 to 120 euros, Invest Securities reiterates its ‘buy’ opinion on bioMérieux, ‘an unfairly discounted stock in the…
bioMérieux: Invest Securities reiterates its opinion
(CercleFinance.com) – While lowering its price target from 127 to 120 euros, Invest Securities reiterates its ‘buy’ opinion on bioMérieux, ‘an unfairly discounted stock in the IVD (in vitro diagnostics)…
Biomérieux at half mast after unsurprising 2023 results
(AOF) – Biomérieux (-1.72% to 98.72 euros) shows one of the biggest drops in the SBF120 after the presentation of its annual results. The in vitro diagnostics specialist published net…
bioMérieux renews its medical and R&D management
(AOF) – bioMérieux announces the appointment of two new leaders: Dr. Charles K. Cooper becomes executive director in charge of medical affairs while Céline Roger-Dalbert will be executive director in…
bioMérieux renews its medical and R&D management – 01/16/2024 at 10:43
(AOF) – bioMérieux announces the appointment of two new leaders: Dr. Charles K. Cooper becomes executive director in charge of medical affairs while Céline Roger-Dalbert will be executive director in…
bioMérieux: CE marking of the VIDAS TBI test in head trauma
AB Published on 10/13/2023 at 7:49 a.m. Photo credit © bioMerieux Company (Boursier.com) — bioMérieux announces…
bioMérieux: CE marking for its blood test against head trauma
(AOF) – bioMérieux announces the CE marking of VidasTBI, a blood test for the evaluation and management of patients with mild head trauma. The in vitro diagnostic specialist specifies that…
bioMérieux: CE marking for its blood test against head trauma – 10/13/2023 at 10:03
(AOF) – bioMérieux announces the CE marking of VidasTBI, a blood test for the evaluation and management of patients with mild head trauma. The in vitro diagnostic specialist specifies that…
Biomerieux: Well oriented with comments from brokers
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
bioMérieux: well oriented with comments from brokers
(CercleFinance.com) – bioMérieux gains 2% and thus outperforms the trend in Paris, supported by favorable remarks from brokers after the publication of the results of the in vitro diagnostics group…
bioMérieux: many advantages in hand
By Jean-Baptiste Andre Published on 08/21/2023 at 1:51 p.m. TP ICAP Midcap reiterates its ‘buy’ advice and its target of 109 euros on bioMerieux…
bioMérieux: stock on the rise, a broker raises its board
(CercleFinance.com) – bioMérieux gained nearly 2% on the Paris stock exchange after Oddo BHF raised its recommendation on the stock from ‘neutral’ to ‘outperforming’ and bringing it into its ‘European…